Replikun Biotech is a immunotherapy company founded in March 2005. The company is focused on the development and commercialization of immunotherapies to combat infectious diseases and cancer. Replikun offers licensing and collaboration opportunities based on KUNrep Vectors, its gene delivery and expression technology. The technology is underpinned by an integrated portfolio of granted and pending patent applications which comprise the KUNrep Vectors, their pharmaceutical applications and methods of manufacture. Replikun Biotech is conducting pre-clinical studies of two products: an investigational oncology candidate and a HIV vaccine, both developed using the KUNrep Vector system.

Hawaii Biotech is a biotechnology company engaged in the development of vaccines and medical countermeasures for infectious diseases. The company's offerings include recombinant protein vaccines for various emerging and re-emerging diseases, and small molecule drugs for treating anthrax and botulism. Hawaii Biotech also produces proteins and saponin adjuvants to enhance immune responses. It was founded in 1982 and is based in Honolulu, Hawaii.

Norgen Biotek is a biotechnology company involved in the life sciences and molecular diagnostics sectors. The company offers nucleic acid extraction, next generation sequencing, and sample collection and preservation tools for scientific research. Norgen Biotek serves the scientific community and provides solutions for sample analysis and biomolecular research. It was founded in 1998 and is based in Thorold, Ontario.

REGiMMUNE is a biotechnology company focusing on the development of medicines related to immune system modulation. The company's treatments focus on inducing tolerance or creating an anti-tumor immune response. REGiMMUNE's offerings include therapies that regulate the immune system, particularly through the use of regulatory T cells. It was founded in 2006 and is based in Tokyo, Japan.

Cognetix specializes in audio communication devices within the electronics sector. The company offers a range of headsets designed for clear and sharp voice communication, featuring noise cancellation technology for professional and personal use. Cognetix primarily serves the telecommunications and consumer electronics sectors. It was founded in 1996 and is based in Salt Lake City, Utah.

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.